WT1 and leukemia: Although further investigation is needed to determine if azacitidine acts preferentially on leukemia cells by increasing WT1 expression, thereby promoting antigen-recognition, and/or TTCR-C4 effector functions, these results support evaluating azacitidine as a favorable adjunct to T-cell immunotherapy.